AxoProtego Therapeutics holds a worldwide license from The Johns Hopkins University in the field of neuroprotection for Ethoxyquin and its derivatives including EQ-6 and EQ-8.
EQ-6 is the Company’s lead drug candidate. AxoProtego is currently focused on developing this small molecule for the prevention of chemotherapy-induced peripheral neuropathy (CIPN), a common and dose-limiting complication of many chemotherapy drugs affecting several million people in the U.S. EQ-6 exhibits in vivo neuroprotective effects while not affecting the chemotherapeutic activity of paclitaxel and cisplatin. EQ-6 protects axons by blocking the initiation of neurodegeneration through its action with HSP90, a heat shock protein and chaperone. EQ-6 is bioavailable both orally and via IV, with demonstrated rapid accumulation in the peripheral nerves.
The Company has been granted method of use patent protection for Ethoxyquin, and composition of matter patents for several novel analogs including EQ-6 and EQ-8.
EQ-8 was recently designed to have increased water solubility, oral bioavailability and can rapidly cross the blood-brain barrier. EQ-8 is being developed for future applications in neurodegenerative diseases such as multiple sclerosis (MS) and Parkinson’s Disease.